SCHEMBL4418526

SCHEMBL4418526

CNc1cc2c(cn1)cc(-c1cc(NC(=O)Nc3cc(C(C)C)nn3-c3ccccc3)c(F)cc1C)c(=O)n2C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 8/20 0.51
RAF1 P04049 6/20 0.51
KRAS P01116 4/20 0.51
KDR P35968 4/20 0.51
MAP2K2 P36507 4/20 0.51
MAP2K1 Q02750 4/20 0.51
KIT P10721 1/20 0.50
PDGFRA P16234 1/20 0.50
KCNJ6 P48051 5/20 0.47
KCNJ5 P48544 5/20 0.47
KCNJ3 P48549 5/20 0.47
MAPK14 Q16539 3/20 0.45
MAPK12 P53778 2/20 0.45
MAPK13 O15264 1/20 0.45
MAPK11 Q15759 1/20 0.45
SRC P12931 2/20 0.41
FGFR1 P11362 1/20 0.41
ARAF P10398 1/20 0.40
HCK P08631 1/20 0.39
NTRK1 P04629 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5057531 0.97 RAF1 (0.49) BRAFRAF1KRASKDRMAP2K2
SCHEMBL5062792 0.92 KIT (0.49) BRAFRAF1KRASKDRMAP2K2
SCHEMBL5061772 0.91 RAF1 (0.63) BRAFRAF1KRASKDRMAP2K2
SCHEMBL4566603 0.89 BRAF (0.52) BRAFRAF1KRASKDRMAP2K2
SCHEMBL4417370 0.87 BRAF (0.60) BRAFRAF1KRASKDRMAP2K2
SCHEMBL5065212 0.84 BRAF (0.58) BRAFRAF1KRASKDRMAP2K2
SCHEMBL5062767 0.83 BRAF (0.47) BRAFRAF1KRASKDRMAP2K2
SCHEMBL5057532 0.83 BRAF (0.37) BRAFRAF1KRASKDRMAP2K2
SCHEMBL27758130 0.83 KIT (0.59) BRAFRAF1KRASKDRMAP2K2
SCHEMBL5057469 0.83 RAF1 (0.56) BRAFRAF1KRASKDRMAP2K2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101553232-A Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS LLC (US) 2009-10-07 CN claimed
EP-2063897-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Deciphera Pharmaceuticals, LLC. (US) 2009-06-03 EP claimed
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PARMACEUTICALS, LLC (US) 2008-05-15 US claimed
WO-2008034008-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC. (US) 2008-03-20 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 BRAF 1/4885RAF1 3/4885KRAS 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.